{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:42:20Z","timestamp":1791308540743,"version":"4.3.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI158013\/R21AI138771"],"award-info":[{"award-number":["R01AI158013\/R21AI138771"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11904-022-00618-w","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T07:08:00Z","timestamp":1659683280000},"page":"425-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["COVID-19 Outcomes and Risk Factors Among People Living with HIV"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6368-8664","authenticated-orcid":false,"given":"Matthew A.","family":"Spinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L. H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"618_CR1","unstructured":"Lamontagne E. COVID-19 pandemic increases socioeconomic vulnerability of LGBTI+ communities and their susceptibility to HIV. AIDS 2020 San Francisco\/Oakland 2020. July 14. abstract LBPEE53."},{"key":"618_CR2","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance Report, 2020; vol. 33. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html. Published May 2022. Accessed June 2 2022."},{"issue":"1","key":"618_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/cid\/ciz728","volume":"71","author":"HM Garcia Garrido","year":"2020","unstructured":"Garcia Garrido HM, Mak AMR, Wit F, et al. Incidence and risk factors for invasive pneumococcal disease and community-acquired pneumonia in human immunodeficiency virus-infected individuals in a high-income setting. Clin Infect Dis. 2020;71(1):41\u201350.","journal-title":"Clin Infect Dis"},{"key":"618_CR4","doi-asserted-by":"crossref","unstructured":"Sachdev D, Mara E, Hsu L, et al. COVID-19 Susceptibility and outcomes among people living with HIV in San Francisco. J Acquir Immune Defic Syndr. 2020;86(1):19\u201321.","DOI":"10.1097\/QAI.0000000000002531"},{"issue":"12","key":"618_CR5","doi-asserted-by":"publisher","first-page":"e1021","DOI":"10.1093\/cid\/ciaa1793","volume":"72","author":"SL Braunstein","year":"2020","unstructured":"\u2022\u2022 Braunstein SL, Lazar R, Wahnich A, Daskalakis DC, Blackstock OJ. Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in New York City: a population-level analysis of linked surveillance data. Clin Infect Dis. 2020;72(12):e1021\u20139. Braunstein and colleagues present a methodolocially rigorous examination of the impact of HIV status on COVID-19 outcomes among PLWH in New York City. This study also demonstrated the impact of racial\/ethnic and socioeconomic disparities on COVID-19 outcomes.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"618_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/QAD.0000000000001712","volume":"32","author":"ME Fitzpatrick","year":"2018","unstructured":"Fitzpatrick ME, Kunisaki KM, Morris A. Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy. AIDS. 2018;32(3):277\u201392.","journal-title":"AIDS"},{"issue":"3","key":"618_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccm.2007.06.004","volume":"28","author":"K Crothers","year":"2007","unstructured":"Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med. 2007;28(3):575\u201387, vi.","journal-title":"Clin Chest Med"},{"key":"618_CR8","doi-asserted-by":"crossref","unstructured":"Meyerowitz EA, Kim AY, Ard KL, et al. Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. AIDS 2020; 34(12).","DOI":"10.1097\/QAD.0000000000002607"},{"issue":"5","key":"618_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.7326\/M14-0954","volume":"162","author":"R Mdodo","year":"2015","unstructured":"Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335\u201344.","journal-title":"Ann Intern Med"},{"issue":"3","key":"618_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2105\/AJPH.2021.306538","volume":"112","author":"ND Goldstein","year":"2022","unstructured":"Goldstein ND, Webster JL, Robinson LF, Welles SL. Disparities of COVID-19 and HIV occurrence based on neighborhood infection incidence in Philadelphia, Pennsylvania. Am J Public Health. 2022;112(3):408\u201316.","journal-title":"Am J Public Health"},{"issue":"6","key":"618_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10903-021-01281-w","volume":"23","author":"AI Zlot","year":"2021","unstructured":"Zlot AI, Capizzi J, Bush L, Menza TW. Impact of COVID-19 Among immigrant and communities of color living with HIV in Oregon, 2020: two pandemics rooted in racism. J Immigr Minor Health. 2021;23(6):1348\u201353.","journal-title":"J Immigr Minor Health"},{"issue":"2","key":"618_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/cid\/ciq110","volume":"52","author":"AN Sheth","year":"2011","unstructured":"Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis. 2011;52(2):219\u201327.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"618_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11904-013-0168-6","volume":"10","author":"VA Triant","year":"2013","unstructured":"Triant VA. Cardiovascular disease and HIV infection. Curr HIV\/AIDS Rep. 2013;10(3):199\u2013206.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"11","key":"618_CR14","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/cid\/ciaa1046","volume":"72","author":"MJ Silverberg","year":"2021","unstructured":"Silverberg MJ, Leyden W, Hern\u00e1ndez-Ram\u00edrez RU, et al. Timing of antiretroviral therapy initiation and risk of cancer among persons living with human immunodeficiency virus. Clin Infect Dis. 2021;72(11):1900\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"618_CR15","doi-asserted-by":"publisher","first-page":"e000304","DOI":"10.1136\/bmjdrc-2016-000304","volume":"5","author":"AC Hernandez-Romieu","year":"2017","unstructured":"Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009\u20132010. BMJ Open Diabetes Res Care. 2017;5(1):e000304.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"618_CR16","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S2352-3018(21)00072-2","volume":"8","author":"MA Spinelli","year":"2021","unstructured":"Spinelli MA, Lynch KL, Yun C, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. The Lancet HIV. 2021;8(6):e334\u201341.","journal-title":"The Lancet HIV"},{"issue":"3","key":"618_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/cei.12619","volume":"181","author":"MB Buechler","year":"2015","unstructured":"Buechler MB, Newman LP, Chohan BH, Njoroge A, Wamalwa D, Farquhar C. T cell anergy and activation are associated with suboptimal humoral responses to measles revaccination in HIV-infected children on anti-retroviral therapy in Nairobi. Kenya Clin Exp Immunol. 2015;181(3):451\u20136.","journal-title":"Kenya Clin Exp Immunol"},{"issue":"12","key":"618_CR18","doi-asserted-by":"publisher","first-page":"e0005219","DOI":"10.1371\/journal.pntd.0005219","volume":"10","author":"VI Avelino-Silva","year":"2016","unstructured":"Avelino-Silva VI, Miyaji KT, Hunt PW, et al. CD4\/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients. PLoS Negl Trop Dis. 2016;10(12):e0005219.","journal-title":"PLoS Negl Trop Dis"},{"issue":"16","key":"618_CR19","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1097\/QAD.0000000000001963","volume":"32","author":"N Colin de Verdiere","year":"2018","unstructured":"Colin de Verdiere N, Durier C, Samri A, et al. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. AIDS. 2018;32(16):2291\u20139.","journal-title":"AIDS"},{"issue":"11","key":"618_CR20","doi-asserted-by":"publisher","first-page":"e79816","DOI":"10.1371\/journal.pone.0079816","volume":"8","author":"A Parmigiani","year":"2013","unstructured":"Parmigiani A, Alcaide ML, Freguja R, et al. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One. 2013;8(11):e79816.","journal-title":"PLoS One"},{"key":"618_CR21","doi-asserted-by":"publisher","unstructured":"Spinelli MA. SARS-CoV-2 vaccination in people with HIV. The Lancet HIV 2021. Epub ahead of print https:\/\/doi.org\/10.1016\/S2352-3018(21)00128-4.","DOI":"10.1016\/S2352-3018(21)00128-4"},{"issue":"3","key":"618_CR22","first-page":"157","volume":"11","author":"R van den Berg","year":"2009","unstructured":"van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev. 2009;11(3):157\u201364.","journal-title":"AIDS Rev"},{"issue":"2","key":"618_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7326\/0003-4819-109-2-101","volume":"109","author":"AC Collier","year":"1988","unstructured":"Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988;109(2):101\u20135.","journal-title":"Ann Intern Med"},{"key":"618_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2334-6-65","volume":"6","author":"N Pasricha","year":"2006","unstructured":"Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC Infect Dis. 2006;6:65.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"618_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/clinids\/21.5.1197","volume":"21","author":"FP Kroon","year":"1995","unstructured":"Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis. 1995;21(5):1197\u2013203.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"618_CR26","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/infdis\/jiy310","volume":"218","author":"C von Mollendorf","year":"2018","unstructured":"von Mollendorf C, Hellferscee O, Valley-Omar Z, et al. Influenza viral shedding in a prospective cohort of HIV-infected and uninfected children and adults in 2 provinces of South Africa, 2012\u20132014. J Infect Dis. 2018;218(8):1228\u201337.","journal-title":"J Infect Dis"},{"issue":"1","key":"618_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","volume":"22","author":"M Antonelli","year":"2022","unstructured":"Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"618_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/COH.0000000000000659","volume":"16","author":"LB Brown","year":"2021","unstructured":"Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: summary of the data and responses to date. Curr Opin HIV AIDS. 2021;16(1):63\u201373.","journal-title":"Curr Opin HIV AIDS"},{"key":"618_CR29","doi-asserted-by":"crossref","unstructured":"Rutishauser RL, Hartogensis W, Deguit CD, et al. Early and delayed antiretroviral therapy results in comparable reductions in CD8(+) T cell exhaustion marker expression. AIDS Res Hum Retroviruses. 2017;33(7):658\u201367.","DOI":"10.1089\/aid.2016.0324"},{"issue":"7","key":"618_CR30","doi-asserted-by":"publisher","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","volume":"12","author":"R Fromentin","year":"2016","unstructured":"Fromentin R, Bakeman W, Lawani MB, et al. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 2016;12(7):e1005761.","journal-title":"PLoS Pathog"},{"key":"618_CR31","unstructured":"\u2022\u2022 Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med 2022. This prospective cohort study among HIV clinics in 60 hospitals that serve over 75,000 PLWH in Madrid observed lower risk of SARS-CoV-2 infection among PLWH on ART compared to the general population, although the risk was similar between PLWH and the general population once health care workers were excluded."},{"key":"618_CR32","doi-asserted-by":"crossref","unstructured":"Huang J, Xie N, Hu X, et al. Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: a population-based cohort study. Clin Infect Dis. 2020;73(7):e2086\u2013e2094.","DOI":"10.1093\/cid\/ciaa1186"},{"issue":"2","key":"618_CR33","doi-asserted-by":"publisher","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","volume":"4","author":"JM Tesoriero","year":"2021","unstructured":"\u2022\u2022 Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed hiv infection in New York state. JAMA Netw Open. 2021;4(2):e2037069. This study by Tesoriero and colleagues demonstrates the impact of living with HIV on COVID-19 outcomes in a large population-based sample among PLWH in New York State.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"618_CR34","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/S2352-3018(21)00239-3","volume":"8","author":"X Yang","year":"2021","unstructured":"Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021;8(11):e690\u2013700.","journal-title":"Lancet HIV"},{"key":"618_CR35","doi-asserted-by":"crossref","unstructured":"Boulle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis.\u00a02021;73(7):e2005\u2013e2015.","DOI":"10.1101\/2020.07.02.20145185"},{"key":"618_CR36","doi-asserted-by":"crossref","unstructured":"Spinelli MA, Brown LB, Glidden DV, et al. SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV. AIDS. 2021;35(15):2545\u20137.","DOI":"10.1097\/QAD.0000000000003075"},{"issue":"12","key":"618_CR37","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/QAD.0000000000002639","volume":"34","author":"C Charre","year":"2020","unstructured":"Charre C, Icard V, Pradat P, et al. Coronavirus disease 2019 attack rate in HIV-infected patients and in preexposure prophylaxis users. AIDS. 2020;34(12):1765\u201370.","journal-title":"AIDS"},{"key":"618_CR38","unstructured":"Park LR, CT Rentsch, Sigel K, Rodriguez-Barradas M, Brown ST, Goetz MB, Williams EC, Althoff K, Brau N, Aoun-Barakat L, Tseng A, Justice AC, Tate JP. COVID-19 in the largest US HIV cohort. In: AIDS 2020: 23rd International AIDS Conference Virtual, 2020."},{"key":"618_CR39","doi-asserted-by":"crossref","unstructured":"Santiago-Rodriguez EI, Maiorana A, Peluso MJ, et al. Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery. Int J Behav Med 2021: 1\u201314.","DOI":"10.1007\/s12529-021-10045-7"},{"key":"618_CR40","unstructured":"Tang ME, Gaufin T, Anson R, Zhu W, Mathews William\u00a0C, Cachay ER. People with HIV have a higher risk of COVID-19 diagnosis but similar outcomes to the general population. HIV Medicine."},{"key":"618_CR41","doi-asserted-by":"crossref","unstructured":"Chang JJ, Bruxvoort K, Chen LH, Akhavan B, Rodriguez J, Hechter RC. Brief report: COVID-19 testing, characteristics, and outcomes among people living with HIV in an integrated health system. JAIDS Journal of Acquired Immune Deficiency Syndromes 2021; 88(1).","DOI":"10.1097\/QAI.0000000000002715"},{"issue":"9953","key":"618_CR42","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0140-6736(14)61132-6","volume":"384","author":"S Fazel","year":"2014","unstructured":"Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations. Lancet. 2014;384(9953):1529\u201340.","journal-title":"Lancet."},{"issue":"6 Suppl","key":"618_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10461-007-9276-x","volume":"11","author":"AA Aidala","year":"2007","unstructured":"Aidala AA, Lee G, Abramson DM, Messeri P, Siegler A. Housing need, housing assistance, and connection to HIV medical care. AIDS Behav. 2007;11(6 Suppl):101\u201315.","journal-title":"AIDS Behav"},{"issue":"17","key":"618_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.15585\/mmwr.mm6917e1","volume":"69","author":"E Mosites","year":"2020","unstructured":"Mosites E, Parker EM, Clarke KEN, et al. Assessment of SARS-CoV-2 infection prevalence in homeless shelters - four U.S. Cities, March 27-April 15, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(17):521\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"618_CR45","doi-asserted-by":"crossref","unstructured":"Imbert E, Kinley PM, Scarborough A, et al. Coronavirus disease 2019 (COVID-19) outbreak in a San Francisco homeless shelter. Clin Infect Dis 2020.","DOI":"10.1093\/cid\/ciaa1071"},{"issue":"5","key":"618_CR46","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/S2352-3018(20)30111-9","volume":"7","author":"JL Blanco","year":"2020","unstructured":"Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7(5):e314\u20136.","journal-title":"Lancet HIV"},{"issue":"8","key":"618_CR47","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(20)30164-8","volume":"7","author":"P Vizcarra","year":"2020","unstructured":"Vizcarra P, P\u00e9rez-El\u00edas MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;7(8):e554\u201364.","journal-title":"Lancet HIV"},{"key":"618_CR48","doi-asserted-by":"crossref","unstructured":"Karmen-Tuohy S, Carlucci PM, Zervou FN, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2020;85(1):6\u201310.","DOI":"10.1097\/QAI.0000000000002423"},{"key":"618_CR49","doi-asserted-by":"crossref","unstructured":"Childs K, Post FA, Norcross C, et al. Hospitalized patients with COVID-19 and HIV: a case series. Clin Infect Dis.\u00a02020;71(8):2021\u20132.","DOI":"10.1093\/cid\/ciaa657"},{"key":"618_CR50","doi-asserted-by":"crossref","unstructured":"Collins LF, Moran CA, Oliver NT, et al. Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, GA. Aids. 2020;34(12):1789\u201394.","DOI":"10.1097\/QAD.0000000000002632"},{"key":"618_CR51","doi-asserted-by":"crossref","unstructured":"Meyerowitz EA, Kim AY, Ard KL, et al. Disproportionate burden of COVID-19 among racial minorities and those in congregate settings among a large cohort of people with HIV. Aids.\u00a02020;34(12):1781\u20137.","DOI":"10.1097\/QAD.0000000000002607"},{"issue":"1","key":"618_CR52","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","volume":"8","author":"K Bhaskaran","year":"2021","unstructured":"Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24\u201332.","journal-title":"Lancet HIV"},{"key":"618_CR53","unstructured":"\u2022\u2022 Bertagnolio S, Thwin SS, Silva R, et al. Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform. IAS 2021; July 19, 2021. Abstract 2498. The WHO Global Clinical Platform presents data on the impact of HIV status on COVID-19 outcomes in a large, multi-country sample based on hospitalization data."},{"issue":"7","key":"618_CR54","doi-asserted-by":"publisher","first-page":"ofab272","DOI":"10.1093\/ofid\/ofab272","volume":"8","author":"GA Yendewa","year":"2021","unstructured":"Yendewa GA, Perez JA, Schlick K, Tribout H, McComsey GA. Clinical features and outcomes of coronavirus disease 2019 among people with human immunodeficiency virus in the United States: a multicenter study from a large global health research network (TriNetX). Open Forum Infect Dis. 2021;8(7):ofab272.","journal-title":"Open Forum Infect Dis"},{"key":"618_CR55","doi-asserted-by":"crossref","unstructured":"Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with HIV and coronavirus disease-19. Clin Infect Dis. 2020;73(7):e1964\u201372","DOI":"10.1093\/cid\/ciaa1339"},{"key":"618_CR56","doi-asserted-by":"crossref","unstructured":"Kamis KF, Barbera L, Abdo M, et al. Risk Factors for hospitalization in people with HIV and COVID-19. JAIDS J Acquire Immune Defic Syndr.\u00a02021;88(3):e22.","DOI":"10.1097\/QAI.0000000000002780"},{"key":"618_CR57","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Shapiro AE, Bender Ignacio RA, Whitney BM, et al. Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020. J Acquir Immune Defic Syndr. 2022;90(4):369\u201376. This multi-site U.S. cohort identified novel risk factors for severe COVID-19 including CD4+ T-cell count nadir, which has important implications for prioritization of therapeutics.","DOI":"10.1097\/QAI.0000000000002989"},{"key":"618_CR58","doi-asserted-by":"crossref","unstructured":"Etienne N, Karmochkine M, Slama L, et al. HIV infection and COVID-19: risk factors for severe disease. AIDS. 2020;34(12):1771\u20134.","DOI":"10.1097\/QAD.0000000000002651"},{"key":"618_CR59","unstructured":"Callaway E, Mallapty S. Novavax offers first evidence that COVID vaccines protect people against variants. 2021 Nature News. Available at https:\/\/www.nature.com\/articles\/d41586-021-00268-9. Accessed 2\/1\/21."},{"key":"618_CR60","unstructured":"Peabody R. Have COVID-19 vaccines been tested in people with HIV? NAM AIDSMAP 2021. Accessed Februrary 25. Available at: https:\/\/www.aidsmap.com\/about-hiv\/have-covid-19-vaccines-been-tested-people-hiv."},{"key":"618_CR61","doi-asserted-by":"crossref","unstructured":"Levy I, Wieder \u2013 Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clini Microbiol Infect. 2021;27(12):1851\u20135.","DOI":"10.1016\/j.cmi.2021.07.031"},{"key":"618_CR62","unstructured":"Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial. Lancet HIV.\u00a02021;8(8):e474\u201385."},{"key":"618_CR63","doi-asserted-by":"crossref","unstructured":"Ogbe A, Pace M, Bittaye M, et al. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight.\u00a02022;7(7):e157031.","DOI":"10.1172\/jci.insight.157031"},{"key":"618_CR64","doi-asserted-by":"crossref","unstructured":"Spinelli MA, Peluso MJ, Lynch KL, et al. Differences in post-mRNA vaccination SARS-CoV-2 IgG concentrations and surrogate virus neutralization test response by HIV status and type of vaccine: a matched case-control observational study. Clin Infect Dis.\u00a02021. pp. ciab1009.","DOI":"10.2139\/ssrn.3909785"},{"key":"618_CR65","doi-asserted-by":"crossref","unstructured":"Antinori A, Cicalini S, Meschi S, et al. Humoral and cellular immune response elicited by mRNA vaccination against SARS-CoV-2 in people living with HIV (PLWH) receiving antiretroviral therapy (ART) according with current CD4 T-lymphocyte count. Clin Infect Dis.\u00a02022. pp. ciac238.","DOI":"10.2139\/ssrn.3929972"},{"issue":"5","key":"618_CR66","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3018(22)00041-8","volume":"9","author":"SA Madhi","year":"2022","unstructured":"Madhi SA, Moodley D, Hanley S, et al. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A\/2B trial. Lancet HIV. 2022;9(5):e309\u201322.","journal-title":"Lancet HIV"},{"issue":"5","key":"618_CR67","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2352-3018(22)00033-9","volume":"9","author":"LC Netto","year":"2022","unstructured":"Netto LC, Ibrahim KY, Picone CM, et al. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet HIV. 2022;9(5):e323\u201331.","journal-title":"Lancet HIV"},{"issue":"4","key":"618_CR68","doi-asserted-by":"publisher","first-page":"ofac089","DOI":"10.1093\/ofid\/ofac089","volume":"9","author":"L Tau","year":"2022","unstructured":"Tau L, Turner D, Adler A, et al. SARS-CoV-2 Humoral and cellular immune responses of patients with HIV After vaccination with BNT162b2 mRNA COVID-19 vaccine in the Tel-Aviv Medical Center. Open Forum Infect Dis. 2022;9(4):ofac089.","journal-title":"Open Forum Infect Dis"},{"key":"618_CR69","doi-asserted-by":"publisher","first-page":"n2244","DOI":"10.1136\/bmj.n2244","volume":"374","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after COVID-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244.","journal-title":"BMJ"},{"key":"618_CR70","doi-asserted-by":"crossref","unstructured":"Coburn SB, Humes E, Lang R, et al. COVID-19 infections post-vaccination by HIV status in the United States. medRxiv 2021: 2021.12.02.21267182.","DOI":"10.1101\/2021.12.02.21267182"},{"issue":"11","key":"618_CR71","doi-asserted-by":"publisher","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","volume":"8","author":"C Sepulcri","year":"2021","unstructured":"Sepulcri C, Dentone C, Mikulska M, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study. Open Forum Infect Dis. 2021;8(11):ofab217.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"618_CR72","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1093\/cid\/ciab072","volume":"73","author":"MK Hensley","year":"2021","unstructured":"Hensley MK, Bain WG, Jacobs J, et al. Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study. Clin Infect Dis. 2021;73(3):e815\u201321.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"618_CR73","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","volume":"30","author":"S Cele","year":"2022","unstructured":"Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30(2):154-62.e5.","journal-title":"Cell Host Microbe"},{"key":"618_CR74","doi-asserted-by":"crossref","unstructured":"Rose DT, Gandhi SM, Bedard RA, et al. Supratherapeutic tacrolimus concentrations with nirmatrelvir\/ritonavir in solid organ transplant recipients requiring hospitalization: a case series using rifampin for reversal. Open Forum Infect Dis.\u00a02022;9(7):ofac238.","DOI":"10.1093\/ofid\/ofac238"},{"issue":"16","key":"618_CR75","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474\u201384.","journal-title":"N Engl J Med"},{"key":"618_CR76","doi-asserted-by":"crossref","unstructured":"Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. medRxiv 2022: 2022.01.05.22268800.","DOI":"10.1101\/2022.01.05.22268800"},{"key":"618_CR77","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbi.2022.04.013","volume":"103","author":"M Taquet","year":"2022","unstructured":"Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154\u201362.","journal-title":"Brain Behav Immun"},{"issue":"7","key":"618_CR78","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","volume":"28","author":"Z Al-Aly","year":"2022","unstructured":"Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461\u20137.","journal-title":"Nat Med"},{"issue":"2","key":"618_CR79","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41590-021-01113-x","volume":"23","author":"C Phetsouphanh","year":"2022","unstructured":"Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210\u20136.","journal-title":"Nat Immunol"},{"issue":"5","key":"618_CR80","doi-asserted-by":"publisher","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","volume":"10","author":"S Serrano-Villar","year":"2014","unstructured":"Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.","journal-title":"PLoS Pathog"},{"issue":"6","key":"618_CR81","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/infdis\/jix039","volume":"215","author":"G Khoury","year":"2017","unstructured":"Khoury G, Fromentin R, Solomon A, et al. Human immunodeficiency virus persistence and T-cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy. J Infect Dis. 2017;215(6):911\u20139.","journal-title":"J Infect Dis"},{"issue":"5","key":"618_CR82","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1007\/s11606-021-07379-z","volume":"37","author":"JR Kingery","year":"2022","unstructured":"Kingery JR, Safford MM, Martin P, et al. Health status, persistent symptoms, and effort intolerance one year after acute COVID-19 infection. J Gen Intern Med. 2022;37(5):1218\u201325.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"618_CR83","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/iid3.467","volume":"9","author":"S Pujari","year":"2021","unstructured":"Pujari S, Gaikwad S, Chitalikar A, Dabhade D, Joshi K, Bele V. Long-coronavirus disease among people living with HIV in western India: an observational study. Immun Inflamm Dis. 2021;9(3):1037\u201343.","journal-title":"Immun Inflamm Dis"},{"key":"618_CR84","doi-asserted-by":"crossref","unstructured":"Peluso MJ, Spinelli MA, Deveau T-M, et al. Post-acute sequelae and adaptive immune responses in people living with HIV recovering from SARS-CoV-2 infection. medRxiv 2022: 2022.02.10.22270471.","DOI":"10.1101\/2022.02.10.22270471"},{"issue":"11","key":"618_CR85","doi-asserted-by":"publisher","first-page":"e25639","DOI":"10.1002\/jia2.25639","volume":"23","author":"GA Millett","year":"2020","unstructured":"Millett GA. New pathogen, same disparities: why COVID-19 and HIV remain prevalent in U.S. communities of colour and implications for ending the HIV epidemic. J Int AIDS Soc. 2020;23(11):e25639.","journal-title":"J Int AIDS Soc"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-022-00618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-022-00618-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-022-00618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T08:25:49Z","timestamp":1663921549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-022-00618-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1007\/s11904-022-00618-w","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"27 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}